![](https://endpts.com/wp-content/uploads/2024/05/Kasper-Roet-QurAlis-feature.jpg)
Kasper Roet, QurAlis CEO
Eli Lilly licenses preclinical antisense program designed to treat ALS, dementia
Eli Lilly added another neuroscience program to its pipeline, licensing an antisense oligonucleotide from the ALS biotech QurAlis.
The deal, announced Monday, is the latest …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.